Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodies and free fatty acids. The idea is that they could...

Descripción completa

Detalles Bibliográficos
Autores principales: Vargas-Delgado, Ariana P., Arteaga Herrera, Estefania, Tumbaco Mite, Cesar, Delgado Cedeno, Patricia, Van Loon, Maria Cristina, Badimon, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960541/
https://www.ncbi.nlm.nih.gov/pubmed/36835554
http://dx.doi.org/10.3390/ijms24044144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960541/
https://www.ncbi.nlm.nih.gov/pubmed/36835554
http://dx.doi.org/10.3390/ijms24044144

Ejemplares similares